Marissa Anne Lopez-Pier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marissa Anne Lopez-Pier has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- John P. Konhilas
University of Arizona
2 shared publications Rinku Skaria
Department of Physiology, University of Arizona, Tucson, Arizona
2 shared publicationsDanielle K. Cannon
Department of Physiology, University of Arizona, Tucson, Arizona
1 shared publicationDennis P Pollow
Department of Physiology, University of Arizona, Tucson, Arizona
1 shared publicationEleni Constantopoulos
Department of Physiology, University of Arizona, Tucson, Arizona
1 shared publicationHao Chen
Department of Physiology, University of Arizona, Tucson, Arizona
1 shared publication
Latest Publications
- 15 May 2020
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 319 (1) , H32-H41
Lactobacillus reuteri attenuates cardiac injury without lowering cholesterol in low-density lipoprotein receptor-deficient mice fed standard chow
Disruption of the normal gut microbiome (dysbiosis) is implicated in the progression and severity of myriad disorders, including hypercholesterolemia and cardiovascular disease. Probiotics attenuate and reverse gut dysbiosis to improve cardiovascular risk factors like hypertension and hypercholesterolemia. Lactobacillus reuteri is a well-studied lactic acid-producing probiotic with known cholesterol-lowering properties and anti-inflammatory effects. In the present study, we hypothesized that L. reuteri delivered to hypercholesterolemic low-density lipoprotein receptor knock-out (LDLr KO) mice will reduce cholesterol levels and minimize cardiac injury from an ischemic insult. L. reuteri (1x109 or 50x106 CFU/day) was administered by oral gavage to wild type mice and LDLr KO for up to 6 weeks followed by an ischemia-reperfusion (I/R) protocol. After 4 weeks of gavage, total serum cholesterol in wild type mice receiving saline was 113.5±5.6 mg/dl compared to 113.3±6.8 mg/dl and 101.9±7.5 mg/dl in mice receiving 1x109 or 50x106 CFU/day, respectively. Over the same timeframe, administration of L. reuteri at 1x109 or 50x106 CFU/day did not lower total serum cholesterol (283.0±11.1, 263.3±5.0 and 253.1±7.0 mg/dl; Saline, 1x109 or 50x106 CFU/day, respectively) in LDLr KO mice. Despite no impact on total serum cholesterol, L. reuteri administration significantly attenuated cardiac injury following I/R, as evidenced by smaller infarct sizes when compared to controls in both wild type and LDLr KO groups. In conclusion, daily L. reuteri significantly protected against cardiac injury without lowering cholesterol levels suggesting anti-inflammatory properties of L. reuteri uncoupled from improvements in serum cholesterol.
- 15 May 2020
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 319 (1) , H32-H41
Lactobacillus reuteri attenuates cardiac injury without lowering cholesterol in low-density lipoprotein receptor-deficient mice fed standard chow
Disruption of the normal gut microbiome (dysbiosis) is implicated in the progression and severity of myriad disorders, including hypercholesterolemia and cardiovascular disease. Probiotics attenuate and reverse gut dysbiosis to improve cardiovascular risk factors like hypertension and hypercholesterolemia. Lactobacillus reuteri is a well-studied lactic acid-producing probiotic with known cholesterol-lowering properties and anti-inflammatory effects. In the present study, we hypothesized that L. reuteri delivered to hypercholesterolemic low-density lipoprotein receptor knock-out (LDLr KO) mice will reduce cholesterol levels and minimize cardiac injury from an ischemic insult. L. reuteri (1x109 or 50x106 CFU/day) was administered by oral gavage to wild type mice and LDLr KO for up to 6 weeks followed by an ischemia-reperfusion (I/R) protocol. After 4 weeks of gavage, total serum cholesterol in wild type mice receiving saline was 113.5±5.6 mg/dl compared to 113.3±6.8 mg/dl and 101.9±7.5 mg/dl in mice receiving 1x109 or 50x106 CFU/day, respectively. Over the same timeframe, administration of L. reuteri at 1x109 or 50x106 CFU/day did not lower total serum cholesterol (283.0±11.1, 263.3±5.0 and 253.1±7.0 mg/dl; Saline, 1x109 or 50x106 CFU/day, respectively) in LDLr KO mice. Despite no impact on total serum cholesterol, L. reuteri administration significantly attenuated cardiac injury following I/R, as evidenced by smaller infarct sizes when compared to controls in both wild type and LDLr KO groups. In conclusion, daily L. reuteri significantly protected against cardiac injury without lowering cholesterol levels suggesting anti-inflammatory properties of L. reuteri uncoupled from improvements in serum cholesterol.
- 8 May 2020
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 318 (6) , H1461-H1473
Using 4-vinylcyclohexene diepoxide as a model of menopause for cardiovascular disease
Before menopause, women are protected against cardiovascular disease compared with age-matched men; this protection is gradually lost after menopause. We present the first evidence that demonstrates menopausal females are more susceptible to pathological cardiac remodeling while perimenopausal and cycling females are not. The 4-vinylcyclohexene diepoxide model permits appropriate examination of how increased susceptibility to the pathological process of cardiac remodeling accelerates from pre- to perimenopause to menopause.
- 8 May 2020
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 318 (6) , H1461-H1473
Using 4-vinylcyclohexene diepoxide as a model of menopause for cardiovascular disease
Before menopause, women are protected against cardiovascular disease compared with age-matched men; this protection is gradually lost after menopause. We present the first evidence that demonstrates menopausal females are more susceptible to pathological cardiac remodeling while perimenopausal and cycling females are not. The 4-vinylcyclohexene diepoxide model permits appropriate examination of how increased susceptibility to the pathological process of cardiac remodeling accelerates from pre- to perimenopause to menopause.